Kezar Life Sciences Inc. Common Stock (KZR)

FairStock Score: 63/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I look first for a durable business with predictable earnings and a margin of safety. Kezar Life Sciences fails the predictability test. It is a clinical-stage biotechnology company with no marketed product and no meaningful revenue growth figure in the data. Its lead candidate, zetomipzomib, targets immune-mediated diseases, but the commercial moat, if any, depends on future clinical data and patents, not on present cash flows. Financially, the available figures are weak: EPS is -$6.17, FairStock shows ROE of -59.93% and ROCE of -29.52%, and trailing free cash flow is -$51.8 million. Against a $53.7 million market cap, that is a FairStock-calculated FCF yield of -96.5%, meaning the company burns cash at a pace close to its entire equity value each year. The Piotroski F-Score of 2/9 and Altman Z-Score of -2.98 point to distress. Low debt, with D/E of 0.03, is a positive, but it does not offset the cash burn. At the 2026-05-11 close of $7.29, FairStock calculates P/B of 0.76, so the stock sells below accounting book value. That looks cheap only if the book value is real and the pipeline succeeds; otherwise, future financing can dilute or erode it. The 52-week range of $4.10 to $7.55 and beta of 0.41 show a small, volatile, speculative issue. Growth is a binary clinical event, not a compounding earnings stream. This is not the kind of predictable, moaty business Graham and Buffett favored. I see optionality, not investment quality.

In plain English: Kezar Life Sciences is a small clinical-stage drug developer focused on immune diseases. It has no marketed product, loses money, and burns cash, so the business looks financially weak. The stock trades below the value of its net assets, but that cheapness is speculative because success depends on clinical trials that may or may not work.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-05-11 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer